1. Khan SA, et al. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 10:77-82.
2. Cancer statistics in Russia and CIS in 2008. Eds M.Davydov, E.Aksel. J. of NN Blokhin Russian Cancer Research Center RAMS 2010; vol 21, №2(80), suppl 1.
3. Marino D, et al. Biliary tract carcinomas: from chemotherapy to targeted therapy. Crit Rev Oncol/Hematol (2012), http://dx.doi.Org/10.1016/j.critrevonc.2012.06.006
4. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Brit J Cancer 2007;96:896-902.
5. Valle JW, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Brit J Cancer 2009;101:621-7.
6. Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl. J. Med 2010;362:1273-81.
7. Hashimoto J., et al. Incidence and risk factors for cholangitis during systemic chemotherapy among patients with advanced biliary tract cancer. J Clin Oncol 29: 2011 (suppl 4; abstr 313)
8. Horgan A.M., et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review. J Clin Oncology 2012, vol 30 , №16, 1934-1940/